NASDAQ : IMRN
Immuron Limited — Key statistics
Healthcare · Biotechnology · Australia
Last price 0.92245 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.09M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.99M |
| Enterprise Value | 2.77M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 322.85M |
| Shares Change (YoY) | +28.65% |
| Shares Change (QoQ) | +16.83% |
| Owned by Insiders (%) | 8.97% |
| Owned by Institutions (%) | 47.87% |
| Float | 274.94M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.70 |
| Forward PS | 1.44 |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.26 |
| Quick Ratio | 5.84 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -242.36 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -38.27% |
| Return on Assets (ROA) | -19.14% |
| Return on Invested Capital (ROIC) | -22.81% |
| Return on Capital Employed (ROCE) | -31.37% |
| Weighted Average Cost of Capital (WACC) | 6.84% |
| Revenue Per Employee | $667,036 |
| Profits Per Employee | -$318,229 |
| Employee Count | 8 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.35 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -54.21% |
| 50-Day Moving Average | 1.15 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 31.89 |
| Average Volume (20 Days) | 27,412 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 66,371 |
| Short Previous Month | 61,753 |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.02% |
| Short Ratio (days to cover) | 0.74 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.34M |
| Gross Profit | 3.44M |
| Operating Income | -2.47M |
| Pretax Income | -2.55M |
| Net Income | -2.55M |
| EBITDA | -2.44M |
| EBIT | -2.47M |
| Loss Per Share | -$0.35 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.24M |
| Total Debt | 131,126 |
| Net Cash | 6.11M |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | 7.72M |
| Book Value Per Share | 0.02 |
| Working Capital | 7.73M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.29M |
| Capital Expenditures | -3,332 |
| Depreciation & Amortization | 29,671 |
| Net Borrowing | -30,795 |
| Free Cash Flow | -2.29M |
| FCF Per Share | -$0.01 |
Margins
| Measure | Value |
|---|
| Gross Margin | 64.50% |
| Operating Margin | -46.22% |
| Pretax Margin | -47.71% |
| Profit Margin | -47.71% |
| EBITDA Margin | -45.68% |
| EBIT Margin | -46.22% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -28.65% |
| Shareholder Yield | -28.65% |
| Earnings Yield | -39.92% |
| FCF Yield | -25.18% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.88 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |